Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs
Life · 26.02.2025 · 15 (3) · 368
DOI: 10.3390/life15030368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 26.02.2025. Verfasst von Aurora Alexandra Jurca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea.
Abstract (Originalsprache)
Background/Objectives: Tuberous sclerosis complex (TSC) is a rare, autosomal dominant genetic disorder caused by mutations in the TSC1 and TSC2 genes, which disrupt the regulation of the mammalian target of rapamycin (mTOR) pathway, a critical regulator of cellular growth. The disorder presents as a multisystem condition, with benign tumors (hamartomas) developing in organs such as the brain, skin, heart, kidneys, and lungs, leading to significant clinical variability and impact on quality of life. This review aims to summarize recent advances in the understanding of TSC pathogenesis and clinical variability and evaluate the therapeutic breakthroughs in targeted treatments.
Methods
A narrative review was conducted using various available databases. We applied objective evaluation metrics, such as the impact factor of the journals and the citation count, to assess the quality of the studies.
Results
Targeted therapies, particularly mTOR inhibitors (mTORis), have shown efficacy in reducing hamartoma size, improving neuropsychiatric symptoms, and enhancing patient outcomes. Despite these advances, variability in disease expression poses challenges in diagnosis and individualized management strategies.
Conclusions
Challenges such as early diagnosis, optimizing long-term outcomes, and addressing residual unmet needs remain critical. Future research should prioritize precision medicine approaches and patient-centered care models within centers of expertise to improve treatment efficacy and quality of life for individuals with TSC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Sq., 410081 Oradea, Romania.
- Regional Center of Medical Genetics Bihor, County Emergency Clinical Hospital Oradea (Part of ERN THACA), 410469 Oradea, Romania.
- Department of Genetics, University of Medicine and Pharmacy "Carol Davila", Dionisie Lupu Street, Number 37, District 2, 020021 Bucharest, Romania.
- Faculty of Medicine and Pharmacy, University of Oradea, December Sq., 410081 Oradea, Romania.
ORCID-Profile: Codruta Diana Petchesi, Emilia Severin, Cosmin Mihai Vesa
Förderung
- University of Oradea
Zitieren
APA
Jurca, A. A., Jurca, A. D., Petchesi, C. D., Bembea, D., Jurca, C. M., Severin, E., Jurca, S., & Vesa, C. M. (2025). Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs. Life, 15(3), 368. https://doi.org/10.3390/life15030368
Vancouver
Jurca AA, Jurca AD, Petchesi CD, Bembea D, Jurca CM, Severin E, et al. Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs. Life. 2025;15(3):368. doi:10.3390/life15030368
BibTeX
@article{Jurca2025,
author = {Jurca, Aurora Alexandra and Jurca, Alexandru Daniel and Petchesi, Codruta Diana and Bembea, Dan and Jurca, Claudia Maria and Severin, Emilia and Jurca, Sanziana and Vesa, Cosmin Mihai},
title = {Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs},
journal = {Life},
year = {2025},
volume = {15},
number = {3},
pages = {368},
doi = {10.3390/life15030368}
}
EUVIMED